Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems
The authors describe the ways in which plastic prefilled syringes can be an alternative that provides consistent performance, protects drugs prone to degradation, and enhances patient safety.


Pharmaceutical Technology


This article is part of PharmTech's supplement "Injectable Drug Delivery."

More than two billion prefilled syringes are developed and used each year. The rise of the prefilled syringe as the preferred container for injectable drugs began with Sanofi and Rhône-Poulenc Rorer's successful introduction of syringes for heparins to the European market in the early 1980s. The prefilled syringe market has expanded considerably because of factors such as the growth of biopharmaceuticals, the need to eliminate overfills, the need for precise delivery volumes, the desire for convenient delivery, the quest for cost effectiveness, and the goal of reducing dosage errors (1–4).


Figure 1: Daikyo Crystal Zenith prefillable syringes (Daikyo Seiko, Tokyo). (IMAGES ARE COURTESY OF WEST)
Currently, most prefilled syringes are made of glass, but plastic syringes are gaining popularity, particularly in applications for which glass is an unsuitable delivery system. In the last decade, pharmaceutical protein and peptide drug products have been approved for use with prefilled plastic syringes. One example is a peptide drug product in a Daikyo Crystal Zenith (CZ) syringe (Daikyo Seiko, Tokyo) (see Figure 1). More products using plastic prefilled syringes are in various phases of drug development.

The need for combination-drug delivery systems

Many chronic diseases such as multiple sclerosis and rheumatoid arthritis require the self-administration of injectable treatments. This need has increased interest in combination-drug delivery systems that are safe, convenient, and help improve the administration process.

Pen injectors and multidose cartridges were created for patients who need frequent injections. These devices were limited to specific therapies such as diabetes and growth hormones, which often require weighed dosages or dose titration. Although pen injectors were designed for frequent injections and for patients who require variable dose capabilities, they are not ideal for chronic users of fixed-dose medications, including patients suffering from impaired dexterity. The need for a safe, reliable, easy-to-use, single-dose injection system for these patients soon became apparent.


Figure 2: ConfiDose autoinjector (West, Lionville, PA). (IMAGES ARE COURTESY OF WEST)
Autoinjectors have been recognized as a convenient method for delivering drug products through an intuitive activation mechanism designed especially for patients whose poor dexterity affects their ability to inject a drug treatment effectively with a traditional syringe (see Figure 2). As patients and caregivers become increasingly involved in determining the best treatment option, biopharmaceutical, pharmaceutical, and device companies are adapting to meet consumers' needs.

Traditional systems' performance problems

Autoinjector systems traditionally use 1-mL glass prefilled syringes. These systems have been successful, but they have notable limitations, including performance problems. Recent studies have shown that silicone oil, which is used to increase lubricity in syringe systems, is often distributed unevenly, thus leaving certain areas of the prefilled syringe surface with insufficient lubrication (5). The inconsistent silicone-oil coating can significantly affect the piston-travel and glide forces in autoinjectors. In 2006, commercial lots of a drug product delivered by an autoinjector that contained a glass prefilled syringe were recalled in several European countries because of problems with slow or incomplete delivery of the drug (6). Uneven silicone coating may increase travel forces and cause failures such as incomplete injections.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
13%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
23%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
NSF, Microsoft Team in Cloud Computing
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here